TIM
ALXN

Thompson Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Thompson Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,100
Closed -$753K – 203
2021
Q2 		$753K Hold
4,100
– – 0.11% 131
2021
Q1 		$627K Hold
4,100
– – 0.09% 136
2020
Q4 		$641K Hold
4,100
– – 0.11% 124
2020
Q3 		$469K Buy
+4,100
New +$442K 0.09% 132

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Thompson Investment Management's ALXN Position: Q3 2021 in Review

Thompson Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,100 shares — an estimated $753K sold.

Thompson Investment Management first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $753K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Thompson Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Thompson Investment Management sold 4,100 Alexion Pharmaceuticals shares in Q3 2021, an estimated $753K.
  • Thompson Investment Management first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Thompson Investment Management's Alexion Pharmaceuticals position peaked at $753K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Thompson Investment Management's 13F filing for Q3 2021, filed 13 Oct 2021.